Anavex Life Sciences Corp (AVXL)

[falconer66a]

The ‘potential’ carcinogenicity risk of blarcamesine.

The risk of over-expressing S1R might need careful consideration

Well, thank you. As a biologist I always enjoy learning more cellular biology from investment advisors.

Your reference stated, “S1R is overexpressed in many types of cancer even though the exact mechanisms by which it promotes cell survival are not fully elucidated. This review summarizes the findings describing the roles of S1R in the control of Ca2+ signaling and its involvement in cancer progression.”

The question then becomes, does Anavex 2-73 (blarcamesine) induce an oncogenic (cancer-causing) “overexpression” of the sigma-1 receptor? Is cancer an adverse event (side effect) or vulnerability of blarcamesine therapy?

After years of testing of the drug in all sorts of organisms, including a few humans, I’ve found no references to any sort of studies demonstrating blarcamesine-induced carcinogenicity. If anyone has a reference to such a finding, please post it. So very important. That would shut down or restrict human tests or therapeutic utilizations.

In fact, testing for carcinogenicity is essentially required for proposed new drugs or medical devices. Anavex has conducted or has reference to such studies involving blarcamesine. Clearly, had there ever been a carcinogenity finding for blarcamesine any number of the astute biotech investment advisors who post on this message board would have, early on, hoisted this red flag. So far, no such flags (studies or findings) exist. After more than a decade of studies, cancer is not a discovered adverse event (side effect) of blarcamesine.

https://www.sciencedirect.com/topics/medicine-and-dentistry/carcinogen-testing